You are browsing a general list of trials
Create your profile and get a personalised list of high value trials
100% Matching
Age
Gender
General fitness
Diagnosis
Cancer stage
Previous treatment
Genomic profile
Medical history
Study type: Immunotherapy Study type: Targeted therapy
Found:
10 trials shown from 588 total

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulv

Study number:
NCT05646862
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Targeted therapy, Hormonal therapy

Novartis

Key trial

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890

Study number:
NCT05552469
Cohorts:
1
Study phase:
1
Overall status:
Not yet recruiting
Study type:
Targeted therapy

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

This is a phase II study testing the combination of pembrolizumab with lenvatinib, a multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors 1

Study number:
NCT05286437
Cohorts:
1
Study phase:
2
Overall status:
Recruiting
Study type:
Targeted therapy, Hormonal therapy

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determ

Study number:
NCT05170204
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab pl

Study number:
NCT05377034
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Local/Regional therapies, Immunotherapy, Targeted therapy

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

This Phase 1/ 2 study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma

Study number:
NCT05417932
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Immunotherapy

Novartis

Key trial

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Study number:
NCT05358249
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in com

Study number:
NCT05502237
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes

Study number:
NCT05537740
Cohorts:
1
Study phase:
1
Overall status:
Not yet recruiting
Study type:
Immunotherapy, Targeted therapy, Chemotherapy

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patien

Study number:
NCT05501886
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Targeted therapy, Chemotherapy